Background: The lack of robust estimates of HIV/HCV incidence among people who inject drugs (PWID) in Iran calls for well-designed prospective cohort studies. Successful recruitment and follow-up of PWID in cohort studies may require formative assessment of barriers PWID are faced with in participation and retention in cohort studies and factors they think may facilitate their engagement in such studies. Using a focus group discussion (FGD) format, we conducted a consultation with PWID in southeast Iran to recognize those barriers and motivators. Methods: Using targeted sampling and through snowball referrals, we recruited PWID (aged�18, injected in last 6 months) from community-based drop-in centers (DICs), homeless shelters, and through...
Background: It is unclear whether knowing of current HIV status is associated with change in injecti...
Background: Despite the development of antiretroviral therapy (ART), injection drug users (IDU) cont...
Background: Illicit drug users account for the majority of cases of HCV in the developed world, but ...
BackgroundThe lack of robust estimates of HIV/HCV incidence among people who inject drugs (PWID) in ...
BackgroundThe lack of robust estimates of HIV/HCV incidence among people who inject drugs (PWID) in ...
BackgroundThe lack of robust estimates of HIV/HCV incidence among people who inject drugs (PWID) in ...
Background: Understanding the reasons for loss to follow-up (LTFU) in cohort studies, especially amo...
BACKGROUND: Most people who inject drugs (PWID) in Iran have not undergone recent HIV testing. ...
BackgroundUnderstanding the reasons for loss to follow-up (LTFU) in cohort studies, especially among...
© 2017 Taylor & Francis Group, LLC Background: Little published research have assessed factors pre...
Background: Hepatitis C virus (HCV)-related morbidity and mortality are rising. Despite recent thera...
Background: The HIV prevention cascade complements the HIV treatment cascade and helps evaluate the ...
Background The CTN-0067 CHOICES trial tests implementation of extended-release naltrexone (XR-NTX) v...
BACKGROUND : Treatment of hepatitis C (HCV) among people who inject drugs (PWID) is a critical compo...
Background: It is unclear whether knowing of current HIV status is associated with change in injecti...
Background: It is unclear whether knowing of current HIV status is associated with change in injecti...
Background: Despite the development of antiretroviral therapy (ART), injection drug users (IDU) cont...
Background: Illicit drug users account for the majority of cases of HCV in the developed world, but ...
BackgroundThe lack of robust estimates of HIV/HCV incidence among people who inject drugs (PWID) in ...
BackgroundThe lack of robust estimates of HIV/HCV incidence among people who inject drugs (PWID) in ...
BackgroundThe lack of robust estimates of HIV/HCV incidence among people who inject drugs (PWID) in ...
Background: Understanding the reasons for loss to follow-up (LTFU) in cohort studies, especially amo...
BACKGROUND: Most people who inject drugs (PWID) in Iran have not undergone recent HIV testing. ...
BackgroundUnderstanding the reasons for loss to follow-up (LTFU) in cohort studies, especially among...
© 2017 Taylor & Francis Group, LLC Background: Little published research have assessed factors pre...
Background: Hepatitis C virus (HCV)-related morbidity and mortality are rising. Despite recent thera...
Background: The HIV prevention cascade complements the HIV treatment cascade and helps evaluate the ...
Background The CTN-0067 CHOICES trial tests implementation of extended-release naltrexone (XR-NTX) v...
BACKGROUND : Treatment of hepatitis C (HCV) among people who inject drugs (PWID) is a critical compo...
Background: It is unclear whether knowing of current HIV status is associated with change in injecti...
Background: It is unclear whether knowing of current HIV status is associated with change in injecti...
Background: Despite the development of antiretroviral therapy (ART), injection drug users (IDU) cont...
Background: Illicit drug users account for the majority of cases of HCV in the developed world, but ...